Please login to the form below

Not currently logged in
Email:
Password:

Bristol-Myers Squibb completes $2.5bn acquisition of Inhibitex

Deal with US biopharmaceutical company boosts its presence in hepatitis C

Bristol-Myers Squibb (BMS) has acquired clinical stage biopharmaceutical company Inhibitex in a deal that boosts its presence in hepatitis C.

Inhibitex's lead compound is the oral nucleotide polymerase (NS5B) inhibitor INX-189, which is in phase II trials in combination with pegylated interferon and ribavirin for chronic hepatitis C.

The deal, which cost BMS approximately $2.5bn, is the latest phase in the pharma company's much-touted 'string of pearls' approach to drug development.

This relies on complementing internal R&D with a suite of alliances, partnerships and acquisitions in its core therapeutic areas and Georgia, US-based Inhibitex is the newest 'pearl' in the string of more than a dozen deals BMS has made since 2007

BMS has been signing a series of agreement in an attempt to combine its own hepatitis C drug candidates - led by NS5A replication complex inhibitor daclatasvir (BMS-790052) in phase III - with compounds in development at other companies.

The overall aim is to develop all-oral treatment regimens that could replace the current therapies based on injectable interferon alpha.

Analysts have predicted multibillion dollar sales for a number of oral hepatitis C therapies coming through pharma company pipelines, and the sector has been invigorated recently by approvals for new oral therapies.

These include Merck & Co's Victrelis (boceprevir) and J&J, Vertex Pharmaceuticals and Mitsubishi Tanabe's Incivek/Incivo (telaprevir).

In December 2011 BMS forged an alliance with Johnson & Johnson's Tibotec unit for the development of an all-oral combination therapy based on daclatasvir and Tibotec's NS3 protease inhibitor TMC435. Phase II trials of the regimen are due to start later this year.

14th February 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios

MadMicrobe is an award-winning team of animators and science experts creating photo real life-science animation content for the healthcare and...

Latest intelligence

brian smith science of the deal
The science of the deal
Business development is more like child-raising than you might think...
The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...

Infographics